Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2005 Oct 7;7(3):E513–E522. doi: 10.1208/aapsj070352

Model-based development of gemcabene, a new lipid-altering agent

Jaap W Mandema 1,✉, David Hermann 2, Wenping Wang 1, Tim Sheiner 1, Mark Milad 2, Rebecca Bakker-Arkema 2, Daniel Hartman 2
PMCID: PMC2751254  PMID: 16353929

Abstract

The purpose of this study was to evaluate the value of model-based, quantitative decision making during the development of gemcabene, a novel lipid-altering agent. The decisions were driven by a model of the likely clinical profile of gemcabene in comparison with its competitors, such as 3-hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), the cholesterol absorption inhibitor ezetimibe, and their combination. Dose-response models were developed for the lipid effects (low-density lipoprotein cholesterol [LDL-C] and high-density lipoprotein cholesterol); adverse effects, such as persistent alanine aminotransferase elevation and myalgia; tolerability issues, such as headache; and risk reduction for coronary artery disease-related events for 5 statins, ezetimibe, gemcabene, and their combinations. The integrated model was based on the joint analysis of publicly available summary-level data and proprietary patient-level data and included information from almost 10,000 patients. The model was made available and accessible to the development team by using the Pharsight Drug Model Explorer model visualization technology. The modeling greatly enhanced the understanding of the clinical profile of gemcabene when given alone or in combination with a statin. The interaction between statins and gemcabene for the LDL-C lowering effect was found to be significantly different from the interaction between statins and ezetimibe. Ezetimibe was found to have a pharmacological-independent interaction resulting in additional LDL-C lowering over the entire statin dose range. The gemcabene interaction was found to be less than independent, resulting in almost no additional LDL-C lowering at high-statin doses, although the drug has a significant LDL-C effect when administered alone or in combination with a low dose of a statin. The quick availability of the model after completion of the first phase II trial in the target patient population and the ability of the team to explore the potential clinical efficacy and safety of gemcabene in comparison with alternative treatment options facilitated a quick decision to stop development.

Keywords: statins, gemcabene, ezetimibe, doseresponse, LDL

Full Text

The Full Text of this article is available as a PDF (282.6 KB).

References

  • 1.Bays HB, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003;92:538–543. doi: 10.1016/S0002-9149(03)00721-5. [DOI] [PubMed] [Google Scholar]
  • 2.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ill guidelines. Circulation. 2004;110:227–239. doi: 10.1161/01.CIR.0000133317.49796.0E. [DOI] [PubMed] [Google Scholar]
  • 3.Normand S-L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18:321–359. doi: 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  • 4.Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am Heart J. 2003;145:1036–1045. doi: 10.1016/S0002-8703(03)00106-6. [DOI] [PubMed] [Google Scholar]
  • 5.Mandema JW, Cox E, Alderman J. Therapeutic benefit of Eletriptan compared to Sumatriptan for the acute relief of migraine pain—results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia. 2005;25:715–725. doi: 10.1111/j.1468-2982.2004.00939.x. [DOI] [PubMed] [Google Scholar]
  • 6.Nawrocki JW, Weiss SR, Davidson MH, et al. Reductions of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678–682. doi: 10.1161/01.atv.15.5.678. [DOI] [PubMed] [Google Scholar]
  • 7.U.S. Food and Drug Administration, 2002. NDA 21-445. Zetia (ezetimibe) Medical Reviews. CDER, FDA.
  • 8.Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475–1481. doi: 10.1016/S0002-9149(97)00174-4. [DOI] [PubMed] [Google Scholar]
  • 9.Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study) Am J Cardiol. 1998;81:582–587. doi: 10.1016/S0002-9149(97)00965-X. [DOI] [PubMed] [Google Scholar]
  • 10.U.S. Food and Drug Administration, 1996. NDA 20-702. Lipitor (atorvastatin) Medical Reviews. CDER, FDA.
  • 11.Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of Rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504–508. doi: 10.1016/S0002-9149(01)01727-1. [DOI] [PubMed] [Google Scholar]
  • 12.Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with Pravastatin and Sim vastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk. 2001;8:383–390. doi: 10.1097/00043798-200112000-00008. [DOI] [PubMed] [Google Scholar]
  • 13.Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of Ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1209–1230. doi: 10.1016/S0149-2918(01)80102-8. [DOI] [PubMed] [Google Scholar]
  • 14.Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with Rosuvastatin versus Atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268–275. doi: 10.1016/S0002-9149(01)02226-3. [DOI] [PubMed] [Google Scholar]
  • 15.Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of Rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91:3–10. doi: 10.1016/S0002-9149(03)00003-1. [DOI] [PubMed] [Google Scholar]
  • 16.Olsson AG, Istad H, Luurila O, et al. Effects of Rosuvastatin and Atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044–1051. doi: 10.1067/mhj.2002.128049. [DOI] [PubMed] [Google Scholar]
  • 17.Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of Rosuvastatin compared with Pravastatin and Simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036–1043. doi: 10.1067/mhj.2002.129312. [DOI] [PubMed] [Google Scholar]
  • 18.Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–1097. doi: 10.1016/S0002-9149(02)02798-4. [DOI] [PubMed] [Google Scholar]
  • 19.Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with Simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134. doi: 10.1016/S0735-1097(02)02610-4. [DOI] [PubMed] [Google Scholar]
  • 20.Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of Rosuvastatin and Atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33–41. doi: 10.1016/S0002-9149(02)02994-6. [DOI] [PubMed] [Google Scholar]
  • 21.Knopp RH, Gitter H, Truitt T, et al. Effects of Ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–741. doi: 10.1016/S0195-668X(02)00807-2. [DOI] [PubMed] [Google Scholar]
  • 22.Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of Ezetimibe coadministered with Atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415. doi: 10.1161/01.CIR.0000068312.21969.C8. [DOI] [PubMed] [Google Scholar]
  • 23.Melani L, Mills R, Hassman D, et al. Efficacy and safety of Ezetimibe coadministered with Pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003;24:717–728. doi: 10.1016/S0195-668X(02)00803-5. [DOI] [PubMed] [Google Scholar]
  • 24.Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003;91:418–424. doi: 10.1016/S0002-9149(02)03236-8. [DOI] [PubMed] [Google Scholar]
  • 25.Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet. 1994;343:1554–1556. doi: 10.1016/S0140-6736(94)92945-9. [DOI] [PubMed] [Google Scholar]
  • 26.Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423–1430. doi: 10.1136/bmj.326.7404.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES